Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 6/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9160971 | 0.78 | CYP3A4 (0.48) | ERN1ALOX5PTGS2MAPTGAA | |
| SCHEMBL28851924 | 0.78 | ERN1 (0.36) | ERN1ALOX15ALOX12ALOX5PTGS2 | |
| SCHEMBL1639475 | 0.77 | ERN1 (0.43) | ERN1MAPTGAAALDH1A1KDM4E | |
| SCHEMBL28179999 | 0.77 | ERN1 (0.35) | ERN1ALOX15ALOX12ALOX5PTGS2 | |
| SCHEMBL10689989 | 0.77 | ACHE (0.43) | ERN1ALOX5PTGS2MAPTGAA | |
| SCHEMBL2164186 | 0.77 | CA12 (0.41) | ERN1MAPTALDH1A1USP2CYP3A4 | |
| SCHEMBL28805089 | 0.77 | POLB (0.39) | ERN1ALOX15ALOX12ALOX5PTGS2 | |
| SCHEMBL5658885 | 0.75 | MAPT (0.35) | ALOX5PTGS2MAPTALDH1A1KDM4E | |
| SCHEMBL28600596 | 0.75 | POLB (0.42) | ERN1ALOX15ALOX12MAPTGAA | |
| SCHEMBL5468567 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836179-B1 | PIPERIDINE- AND PIPERAZINE-1-CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE (FAAH) FOR THE TREATMENT OF ANXIETY, PAIN AND OTHER CONDITIONS | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-06 | — | — | EP | claimed |
| US-8530476-B2 | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-10 | — | — | US | claimed |
| US-20100004261-A1 | PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-07 | — | — | US | claimed |
| EP-1836179-A1 | PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-26 | — | — | EP | claimed |
| US-20060173184-A1 | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-03 | — | — | US | claimed |
| WO-2006074025-A1 | PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-13 | — | — | WO | claimed |
| EP-1155001-A4 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | LION BIOSCIENCE AG (DE) | 2003-05-28 | — | — | EP | claimed |
| EP-1155001-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 2001-11-21 | — | — | EP | claimed |
| WO-2000050406-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | LION BIOSCIENCE AG (DE) | 2000-08-31 | — | — | WO | claimed |
| EP-2937341-A1 | 4-(BENZYL)-PIPERAZINE-1-CARBOXYLIC ACID PHENYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE (FAAH) FOR THE TREATMENT OF ANXIETY, PAIN AND OTHER CONDITIONS | Janssen Pharmaceutica N.V. (BE) | 2015-10-28 | — | — | EP | disclosed |
| US-9169224-B2 | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-27 | — | — | US | disclosed |
| EP-1836179-B1 | PIPERIDINE- AND PIPERAZINE-1-CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE (FAAH) FOR THE TREATMENT OF ANXIETY, PAIN AND OTHER CONDITIONS | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-06 | — | — | EP | disclosed |
| US-20130331396-A1 | PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (US) | 2013-12-12 | — | — | US | disclosed |
| US-8530476-B2 | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-10 | — | — | US | disclosed |
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1836179-A1 | PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-26 | — | — | EP | disclosed |
| US-20060173184-A1 | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-03 | — | — | US | disclosed |
| WO-2006074025-A1 | PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-13 | — | — | WO | disclosed |
| EP-1666469-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-6399653-B1 | METABOLISM DIORDERS; CARDIOVASCULAR DISORDERS; NERVOUS SYSTEM DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331396-A1 | PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, USP47 | ERN1 2606/4885ALOX15 223/4885ALOX12 265/4885 |
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | ERN1 784/4885ALOX15 1536/4885ALOX12 1589/4885 |
| US-20060173184-A1 | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase | FAAH, FAAH2, USP47 | ERN1 2606/4885ALOX15 223/4885ALOX12 265/4885 |
| US-20100004261-A1 | PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, USP47 | ERN1 2606/4885ALOX15 223/4885ALOX12 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.